comprehensive -WSS

comprehensive

author：focus 2025-09-28 12:20:28 - browse：2

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections
Next article： CZI to create biohub to build anti

WSS

STAT Summit: The economic case for universal basic health care

For BCIs, commercial hurdles may be bigger than scientific ones

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Roche drug slashes death risk in early

White House drug shortage group privately met with industry

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

focus

comprehensive

explore

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Medical records are filled with copy

OTC birth control: A brief history of over the counter pill design

BioMarin wins approval for gene therapy to treat hemophilia A

'Ancient DNA,' 23andMe reveal African American ancestries

Novavax promises a turnaround & Lilly roils the obesity market

Readout LOUD podcast: Live from the 2023 STAT Summit

knowledge

ProMED, early warning system on disease outbreaks, in peril

STAT Summit: Meghan O’Rourke on making chronic illness visible

OTC birth control: A brief history of over the counter pill design

Results on Novartis prostate cancer therapy could expand its use

Is there really a nursing shortage in the U.S.?

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

hotspot

focus

focus

explore